Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.17 (
MMP-3
)
3,419
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Macrophages, cytokines, and matrix metalloproteinases (MMP) play important roles in atherogenesis. The Ca(2+)-binding protein
S100A12
regulates monocyte migration and may contribute to atherosclerosis by inducing proinflammatory cytokines in macrophages. We found significantly higher
S100A12
levels in sera from patients with coronary artery disease than controls and levels correlated positively with C-reactive protein.
S100A12
was released into the coronary circulation from ruptured plaque in acute coronary syndrome, and after mechanical disruption by percutaneous coronary intervention in stable coronary artery disease. In contrast to earlier studies,
S100A12
did not stimulate proinflammatory cytokine production by human monocytes or macrophages. Similarly, no induction of MMP genes was found in macrophages stimulated with
S100A12
. Because
S100A12
binds Zn(2+), we studied some functional aspects that could modulate atherogenesis.
S100A12
formed a hexamer in the presence of Zn(2+); a novel Ab was generated that specifically recognized this complex. By chelating Zn(2+),
S100A12
significantly inhibited MMP-2, MMP-9, and
MMP-3
, and the Zn(2+)-induced
S100A12
complex colocalized with these in foam cells in human atheroma.
S100A12
may represent a new marker of this disease and may protect advanced atherosclerotic lesions from rupture by inhibiting excessive MMP-2 and MMP-9 activities by sequestering Zn(2+).
...
PMID:Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. 1954 70